Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)

Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)

Zobrazit další vydání (1)

Background The relevance of the cause of kidney disease to prognosis among patients with chronic kidney disease is uncertain. Study Design Observational study. Settings and Participants 6,245 nondialysis participants in the Study of Heart and Renal Protection (SHARP). Predictor Baseline cause of kid...

Podrobná bibliografie
Hlavní autoři:	Haynes, R, Staplin, N, Emberson, J, Herrington, W, Tomson, C, Agodoa, L, Tesar, V, Levin, A, Lewis, D, Reith, C, Baigent, C, Landray, M
Médium:	Journal article
Vydáno:	2014

Podobné jednotky

Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).
Autor: Haynes, R, a další
Vydáno: (2014)

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
Autor: Staplin, N, a další
Vydáno: (2015)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
Autor: Herrington, WG, a další
Vydáno: (2023)

Smoking and adverse outcomes in patients With CKD: the Study of Heart and Renal Protection (SHARP)
Autor: Emberson, J, a další
Vydáno: (2016)

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
Autor: Staplin, N, a další
Vydáno: (2016)

Conventional and genetic evidence on the association between adiposity and CKD
Autor: Zhu, P, a další
Vydáno: (2020)

Impact of CKD on household income
Autor: Morton, R, a další
Vydáno: (2017)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
Autor: Herrington, W, a další
Vydáno: (2016)

Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD
Autor: Lamprea-Montealegre, J, a další
Vydáno: (2019)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
Autor: Zhu, P, a další
Vydáno: (2020)

The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.
Autor: Herrington, W, a další
Vydáno: (2014)

Evidence for the prevention and treatment of stroke in dialysis patients
Autor: Herrington, W, a další
Vydáno: (2014)

Effects of lowering LDL cholesterol on progression of kidney disease.
Autor: Haynes, R, a další
Vydáno: (2014)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
Autor: Mihaylova, B, a další
Vydáno: (2019)

Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
Autor: Baigent, C, a další
Vydáno: (2010)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the study of heart and renal protection
Autor: Reith, C, a další
Vydáno: (2017)

Impact of CKD on Household Income
Autor: Rachael L. Morton, a další
Vydáno: (2018-05-01)

Benefits of lowering cholesterol in chronic kidney disease Reply
Autor: Baigent, C, a další
Vydáno: (2011)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
Autor: Mafham, M, a další
Vydáno: (2017)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
Autor: Storey, B, a další
Vydáno: (2018)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection
Autor: C. Reith, a další
Vydáno: (2017-05-01)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
Autor: Herrington, W, a další
Vydáno: (2018)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
Autor: Herrington, W, a další
Vydáno: (2022)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
Autor: Schlackow, I, a další
Vydáno: (2017)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
Autor: Zhu, P, a další
Vydáno: (2020)

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Autor: Mayne, K, a další
Vydáno: (2024)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Autor: Storey, B, a další
Vydáno: (2017)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
Autor: Mayne, KM, a další
Vydáno: (2024)

Study of Heart and Renal Protection (SHARP).
Autor: Baigent, C, a další
Vydáno: (2003)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Autor: Baigent, C, a další
Vydáno: (2011)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Autor: Baigent, C, a další
Vydáno: (2011)

Determining the relationship between blood pressure, kidney function, and chronic kidney disease: insights from genetic epidemiology
Autor: Staplin, N, a další
Vydáno: (2022)

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
Autor: Cholesterol Treatment Trialists' Collaboration, a další
Vydáno: (2016)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
Autor: Haynes, R, a další
Vydáno: (2018)

Serum free light chains and the risk of ESRD and death in CKD.
Autor: Haynes, R, a další
Vydáno: (2011)

Serum free light chains and the risk of ESRD and death in CKD
Autor: Haynes, R, a další
Vydáno: (2011)

Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
Autor: Mayne, K, a další
Vydáno: (2023)

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
Autor: Staplin, N, a další
Vydáno: (2021)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
Autor: Staplin, N, a další
Vydáno: (2023)

Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study.
Autor: Landray, M, a další
Vydáno: (2010)